Pfizer's Offer Outpaced by Novo's $8.5B Bid Novo Nordisk launched $8.5B bid for Metsera, rivaling Pfizer's $7.3B offer. Pfizer called Novo's bid 'reckless' and harmful to obesity drug competition. Novo Nordisk shows aggression after slow progress in obesity market, competing with Eli Lilly. Business | Competition | Biotech United States 2 months ago